A New Era in Relieving the Burden and Improving Health Outcomes of Children With Growth Hormone Deficiency

To participate in this activity, please:

Growth hormone deficiency (GHD) specialists Sara DiVall, MD, and Kevin Yuen, MD, explore ways to optimize outcomes in the diagnosis and treatment of GHD in children, including considerations for the use of long-acting growth hormone (LAGH) products. Topics include the epidemiology, clinical manifestations, and burden of GHD in children and adolescents, evidence-based diagnosis of GHD, guidelines and recommendations for treatment, integrating shared decision-making with patients and/or their parents to develop and modify the treatment plan, and clinical trial data regarding daily and new and emerging LAGH products.  Case studies based on common clinical scenarios are discussed to examine how to apply this information in clinical practice to optimize long-term self-management.

Editor's Note: The faculty for this activity has disclosed that there is discussion about the use of products for non-FDA approved applications.

Course Credit:

1.50 AMA PRA Category 1 CreditsTM
1.50 ANCC Contact Hours


Opens: 2022-03-18
Closes: 2023-03-18

Target Audience:

This activity was developed for pediatric endocrinologists, pediatricians, nurse practitioners, physician assistants and other healthcare providers who treat children and adolescents with growth and growth hormone disorders.

This activity is supported by an educational grant from Novo Nordisk Inc.

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 1.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Annenberg Center for Health Sciences at Eisenhower is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation.
A maximum of 1.50 contact hours may be earned for successful completion of this activity.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Lynne Kolton Schneider, PhD (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Sara DiVall, MD

    Associate Professor of Pediatrics
    Fellowship Director
    Seattle Children’s Hospital
    Seattle, Washington

  • Kevin Yuen, MD

    Medical Director
    Barrow Pituitary Center
    Barrow Neuroendocrine Clinic
    Phoenix, Arizona

Learning Objectives

  • Implement key treatment recommendations for children and adolescents with growth hormone deficiency
  • Implement shared decision-making to help children and adolescents and their parents select a growth hormone product based on patient characteristics and needs and product labeling
  • Initiate, titrate, and monitor growth hormone therapy in children and adolescents based on patient response and tolerability
  • Describe the safety and efficacy of emerging long-acting recombinant human growth hormone therapies and their potential use in children and adolescents

Faculty Disclosures

Sara DiVall, MD

No relationships to disclose.

Kevin Yuen, MD

Advisory Board: Chiasma, Crinetics, Ipsen, Novartis, Sandoz, Strongbridge

Research Support: Amryt, Ascendis, Corcept, Novartis

Speakers Bureau: Corcept, Novo Nordisk, Recordati